NR1H4 and metabolic dysfunction-associated steatohepatitis: The treatment pipeline for NASH therapy is currently dominated by modulators of the nuclear farnesoid X receptor (FXR, NR1H4) and the peroxisome proliferator-activated receptors (PPARs, NR1C1–3), which act as ligand-activated transcription factors.